Cannabidiol and <i>Cannabis sativa</i> extract protect mice and rats against convulsive agents

Carlini, E. A.; Leite, José Roberto; Tannhauser, Mário; Berardi, A C

doi:10.1111/j.2042-7158.1973.tb10660.x

Cited by 121 publications

(47 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antiepileptic action The first pharmacological actions of CBD described were the antiepileptic and the sedative ones. In 1973, a Brazilian group reported that CBD was active in reducing or blocking convulsions produced in experimental animals by a variety of procedures, 35,36 which was confirmed by another group one year later. 37 At the end of that decade, the same Brazilian group has tested CBD as a treatment for intractable epilepsy in 16 grand-mal patients.…”

Section: Inactive Cannabinoid That Interact With Delta9-thc (1970's)mentioning

confidence: 91%

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

Zuardi

2008

Rev. Bras. Psiquiatr.

356

302

View full text Add to dashboard Cite

Section: Inactive Cannabinoid That Interact With Delta9-thc (1970's)mentioning

confidence: 91%

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

Zuardi

2008

Rev. Bras. Psiquiatr.

356

302

View full text Add to dashboard Cite

“…Other pharmacological effects of CBD have been reported in studies in laboratory animals and humans, such as antiinflammatory (Malfait et al, 2000), anticonvulsant (Carlini et al, 1973;Izquierdo et al, 1973;Cunha et al, 1980), neuroprotective (Hampson et al, 1998), and hormonal effects (Zuardi et al, 1984(Zuardi et al, , 1993a. In addition, the pharmacological profile of CBD is similar to that of clozapine, an 'atypical' antipsychotic drug (Zuardi et al, 1991(Zuardi et al, , 1995, and both CBD and clozapine induce c-fos expression in the prefrontal cortex and lateral septal nucleus in rats (Zuardi et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow

Crippa

Zuardi

Garrido

et al. 2003

Neuropsychopharmacol

261

224

View full text Add to dashboard Cite

Animal and human studies have suggested that cannabidiol (CBD) may possess anxiolytic properties, but how these effects are mediated centrally is unknown. The aim of the present study was to investigate this using functional neuroimaging. Regional cerebral blood flow (rCBF) was measured at rest using 99m Tc-ECD SPECT in 10 healthy male volunteers, randomly divided into two groups of five subjects. Each subject was studied on two occasions, 1 week apart. In the first session, subjects were given an oral dose of CBD (400 mg) or placebo, in a double-blind procedure. SPECT images were acquired 90 min after drug ingestion. The Visual Analogue Mood Scale was applied to assess subjective states. In the second session, the same procedure was performed using the drug that had not been administered in the previous session. Within-subject between-condition rCBF comparisons were performed using statistical parametric mapping (SPM). CBD significantly decreased subjective anxiety and increased mental sedation, while placebo did not induce significant changes. Assessment of brain regions where anxiolytic effects of CBD were predicted a priori revealed two voxel clusters of significantly decreased ECD uptake in the CBD relative to the placebo condition (po0.001, uncorrected for multiple comparisons). These included a medial temporal cluster encompassing the left amygdala-hippocampal complex, extending into the hypothalamus, and a second cluster in the left posterior cingulate gyrus. There was also a cluster of greater activity with CBD than placebo in the left parahippocampal gyrus (po0.001). These results suggest that CBD has anxiolytic properties, and that these effects are mediated by an action on limbic and paralimbic brain areas.

show abstract

“…CBD systemic administration produces several pharmacological effects, including antiinflammatory, immunomodulatory (Malfait et al 2000), anticonvulsive, neuroprotective, antipsychotic, and anxiolytic (Carlini et al 1973;Guimarães et al 1990;Zuardi et al 1995;Moreira and Guimarães 2005). However, the molecular mechanisms underlying these effects remain poorly understood.…”

Section: Introductionmentioning

confidence: 96%

Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats

2008

View full text Add to dashboard Cite

show abstract

Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents

Cited by 121 publications

References 9 publications

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow

Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats

Contact Info

Product

Resources

About